{"meta":{"query_hash":"2c75919a263e","filters":{"venue":"EJC Skin Cancer"},"cohort_total":13,"direct_labels_cover":0,"predictions_cover":13,"exported":13,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/2c75919a263e","api":"https://metacan.xera.ac/api/v1/cohort?venue=EJC+Skin+Cancer"},"results":[{"id":"W4391649234","doi":"10.1016/j.ejcskn.2024.100022","title":"Quality of life issues faced by patients with keratinocyte cancer: A systematic review","year":2024,"lang":"en","type":"review","venue":"EJC Skin Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Quality of life (healthcare); Medicine; Systematic review; Distress; Modalities; MEDLINE; Gerontology; Disease; Pathology; Clinical psychology; Nursing","score_opus":0.05195869532728559,"score_gpt":0.4177770245737574,"score_spread":0.36581832924647184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391649234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017118803,0.9968694,0.00009147768,0.00029848987,0.00007106646,0.00030469918,0.00040313145,0.000005128622,0.0002447192],"genre_scores_gemma":[0.028357156,0.9691362,0.00048782388,0.0007642378,0.00008150039,0.0007757463,0.00028447894,0.0000039427377,0.000108897024],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9925598,0.0026673991,0.002705769,0.00052310224,0.0012995199,0.0002443603],"domain_scores_gemma":[0.97757715,0.015663452,0.004483769,0.00020904337,0.0018256481,0.00024100197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006346807,0.0012352825,0.0061781663,0.007386074,0.00062218634,0.0024388395,0.0012996477,0.0015583646,0.003533493],"category_scores_gemma":[0.032824896,0.0006867269,0.006243114,0.008103877,0.00077274995,0.0020688637,0.0015175749,0.0011494572,0.0001807373],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118436044,0.000015116474,0.0012715341,0.96200657,0.0064508743,0.0000897284,0.00029718282,0.00006575446,0.000081871236,0.00012832263,0.0012515294,0.0282231],"study_design_scores_gemma":[0.0002283283,0.0002237163,0.00797185,0.9233247,0.05021939,0.0006018791,0.0007059607,0.000077227916,0.00011156214,0.00028535185,0.01619952,0.000050555376],"about_ca_topic_score_codex":0.007957131,"about_ca_topic_score_gemma":0.023830554,"teacher_disagreement_score":0.007957131,"about_ca_system_score_codex":0.003767296,"about_ca_system_score_gemma":0.0094177,"threshold_uncertainty_score":0.03356552},"labels":[],"label_agreement":null},{"id":"W4399122510","doi":"10.1016/j.ejcskn.2024.100248","title":"Survival Outcomes in T3N0 versus N1 in Head and Neck Cutaneous Squamous Cell Carcinoma – Implications for Neoadjuvant Immune Checkpoint Inhibitor Immunotherapy","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Head and neck; Immunotherapy; Oncology; Head and neck squamous-cell carcinoma; Basal cell; Immune checkpoint; Complete response; Internal medicine; Radiation therapy; Head and neck cancer; Chemotherapy; Cancer; Surgery","score_opus":0.02633942168190365,"score_gpt":0.3271439383847343,"score_spread":0.30080451670283065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122510","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018567491,0.9782748,0.00029453708,0.0005440888,0.0001174988,0.00015849764,0.0015214939,0.000008058353,0.00051342807],"genre_scores_gemma":[0.5471441,0.44525725,0.0015904967,0.0020591156,0.00038479175,0.0011456059,0.0020490985,0.00002766135,0.00034182824],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.98984563,0.0039379024,0.0043752217,0.0009596075,0.00071312825,0.00016842512],"domain_scores_gemma":[0.9741633,0.017105406,0.006563397,0.0005606929,0.0013892677,0.00021795396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014479425,0.0006511559,0.0059922524,0.0051344642,0.0002783097,0.0019471295,0.0009155876,0.0010879962,0.0014590702],"category_scores_gemma":[0.03095792,0.0005180884,0.012988108,0.0061398605,0.00065672357,0.0011593015,0.00086925353,0.0007064443,0.00014337643],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006935619,0.000035405505,0.054261535,0.6595754,0.21684049,0.00020367932,0.0003454341,0.0006716756,0.00079423096,0.00046796168,0.0020058614,0.057862688],"study_design_scores_gemma":[0.0021912456,0.0008477466,0.12361907,0.18568736,0.67297965,0.0006698219,0.000566711,0.0005006673,0.0005208309,0.0015537688,0.010760882,0.00010214007],"about_ca_topic_score_codex":0.004914119,"about_ca_topic_score_gemma":0.012243241,"teacher_disagreement_score":0.014479425,"about_ca_system_score_codex":0.0019214639,"about_ca_system_score_gemma":0.0026630017,"threshold_uncertainty_score":0.07657546},"labels":[],"label_agreement":null},{"id":"W4399122701","doi":"10.1016/j.ejcskn.2024.100143","title":"A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Nivolumab; Medicine; Pharmacokinetics; Safety profile; Metastatic melanoma; Melanoma; Oncology; Pharmacology; Internal medicine; Anesthesia; Adverse effect; Cancer; Immunotherapy; Cancer research","score_opus":0.026175707076226656,"score_gpt":0.35289931568384625,"score_spread":0.3267236086076196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943968,0.0007344535,0.0006138687,0.00028259106,0.00017514863,0.0013557116,0.0011188878,0.000098492834,0.0012240062],"genre_scores_gemma":[0.98867387,0.0009310872,0.0021275878,0.0006949998,0.00022693965,0.0020113392,0.0021048211,0.00008771844,0.0031415892],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99923706,0.00031428997,0.00002218049,0.00016109427,0.00006577637,0.00019963107],"domain_scores_gemma":[0.9989536,0.00018038304,0.00017139525,0.00014038401,0.000053972242,0.0005002953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021243384,0.0020061247,0.003010283,0.0006939989,0.00059552514,0.0015178691,0.0011159127,0.0014524187,0.0040492313],"category_scores_gemma":[0.0012425807,0.00093514123,0.0030031106,0.0006000724,0.0016178649,0.0011668879,0.00039449832,0.0058784373,0.0012733114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82475317,0.09775673,0.0017963259,0.0002868263,0.0013618274,0.00012177545,0.00025048683,0.0022508744,0.03191299,0.00027221223,0.0021004851,0.037136372],"study_design_scores_gemma":[0.4355563,0.55474645,0.0040478264,0.000013267445,0.00043337946,0.000110114044,0.00005256532,0.0011252034,0.0027644942,0.00018531813,0.0009297109,0.000035494755],"about_ca_topic_score_codex":0.0024716705,"about_ca_topic_score_gemma":0.0038741964,"teacher_disagreement_score":0.0040492313,"about_ca_system_score_codex":0.0014913299,"about_ca_system_score_gemma":0.00255078,"threshold_uncertainty_score":0.01354605},"labels":[],"label_agreement":null},{"id":"W4399122791","doi":"10.1016/j.ejcskn.2024.100087","title":"Estimating Occupational Exposure to Ultraviolet Radiation Using the Canadian Occupation Exposure Matrix (CANJEM) in a Nationwide Cohort of French Adults","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Air Quality and Health Impacts","field":"Environmental Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Occupational exposure; Ultraviolet radiation; Job-exposure matrix; Radiation exposure; Environmental health; Cohort; Medicine; Environmental science; Nuclear medicine; Radiochemistry; Chemistry; Pathology","score_opus":0.02546508462888969,"score_gpt":0.3471180471206083,"score_spread":0.3216529624917186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967564,0.0005419424,0.00017869772,0.000095782714,0.000008875953,0.000035321074,0.0013406817,0.0000131816905,0.001029082],"genre_scores_gemma":[0.99772483,0.0002930245,0.0003209959,0.00008123304,0.000007861029,0.000028032238,0.00097253773,0.0000033393828,0.00056815904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999421,0.00008324346,0.000033821045,0.0001292481,0.0001536309,0.00017913339],"domain_scores_gemma":[0.9992174,0.00008510628,0.00017105998,0.000059950657,0.00029092346,0.00017565262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013883403,0.0005342219,0.00029698623,0.0018788028,0.001326899,0.0009751362,0.00078971015,0.00072108576,0.0016885945],"category_scores_gemma":[0.0016375063,0.00025954968,0.0007801095,0.0015069304,0.0003808195,0.00034323015,0.0005879343,0.00045441856,0.00033929452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033494398,0.000019311667,0.9978338,0.000008439522,0.000021829435,0.000039500304,0.00018675385,0.00003200795,0.00007551117,0.000014241689,0.00026458764,0.001470612],"study_design_scores_gemma":[0.0000020581488,0.000044417517,0.9987264,0.000010022675,0.000014006773,0.00010149048,0.00045516097,0.00016975576,0.000024035007,0.0000066499156,0.00044089073,0.0000050159492],"about_ca_topic_score_codex":0.86660707,"about_ca_topic_score_gemma":0.8344706,"teacher_disagreement_score":0.86660707,"about_ca_system_score_codex":0.0062134345,"about_ca_system_score_gemma":0.0036539445,"threshold_uncertainty_score":0.26835698},"labels":[],"label_agreement":null},{"id":"W4399128155","doi":"10.1016/j.ejcskn.2024.100072","title":"ANALYSIS OF GLOBAL Skin-Cancer Epidemiology and Correlation with Dermatologist Density and Population Risk Factors","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Future Earth","funders":"","keywords":"Epidemiology; Skin cancer; Dermatology; Medicine; Correlation; Demography; Cancer; Internal medicine; Mathematics","score_opus":0.01726049559795837,"score_gpt":0.3143669913361692,"score_spread":0.2971064957382108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399128155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99315405,0.0010863189,0.0009096009,0.00022855928,0.000024719668,0.000017277725,0.0012542093,0.000048820893,0.003276528],"genre_scores_gemma":[0.99889416,0.00012817346,0.0001581554,0.000014240503,0.000013478562,0.00000686066,0.00028015126,0.0000056388362,0.00049919746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995802,0.00013598644,0.00004038838,0.00010257094,0.000065680964,0.000075150856],"domain_scores_gemma":[0.998283,0.00056361465,0.00041076975,0.00017461627,0.00019846996,0.0003695026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057486317,0.00018164382,0.00025724104,0.0011328888,0.00022601032,0.00047003044,0.00019469095,0.00023531412,0.008013328],"category_scores_gemma":[0.0020862392,0.0001394248,0.00066399976,0.0011345077,0.00022499227,0.0002738783,0.0004001948,0.00047107154,0.00049886794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000038201222,0.000010379342,0.99827695,0.000007820928,0.00007134226,0.0000395808,0.000018995404,0.000073000534,0.00009862514,0.000039588613,0.00010097244,0.0012245708],"study_design_scores_gemma":[0.0000015523862,0.000042895575,0.9988238,0.0000053375825,0.00003938475,0.00027763523,0.00010738985,0.00033427202,0.000045361317,0.00004665908,0.00027317504,0.0000024768433],"about_ca_topic_score_codex":0.0052372785,"about_ca_topic_score_gemma":0.0039991154,"teacher_disagreement_score":0.008013328,"about_ca_system_score_codex":0.00021307296,"about_ca_system_score_gemma":0.00043440165,"threshold_uncertainty_score":0.026807308},"labels":[],"label_agreement":null},{"id":"W4402731446","doi":"10.1016/j.ejcskn.2024.100267","title":"Sonidegib reduced tumor burden in patients with advanced basal cell carcinoma in the BOLT trial: Long-term analysis results","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research","funders":"Sun Pharma","keywords":"Basal cell carcinoma; Term (time); Medicine; Oncology; Internal medicine; Basal cell; Physics","score_opus":0.010212480374670724,"score_gpt":0.2700852698998302,"score_spread":0.2598727895251595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402731446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771861,0.013330423,0.0005543288,0.0006894228,0.000082090875,0.0005700992,0.0046117636,0.000078004035,0.0028978186],"genre_scores_gemma":[0.9885804,0.0022485096,0.00054326147,0.0004801321,0.00014360045,0.00074705295,0.005598056,0.0000227345,0.0016362234],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99879897,0.00056163815,0.00007955194,0.00020822967,0.00022801198,0.00012358763],"domain_scores_gemma":[0.99856657,0.00034222612,0.0004847223,0.00013040514,0.00017788082,0.00029828664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003217368,0.00056658266,0.0015178524,0.0002532626,0.00027460413,0.001176371,0.0003776158,0.00051955413,0.0027515707],"category_scores_gemma":[0.0026557825,0.00018146758,0.0021975562,0.00040799024,0.0003365523,0.00075304066,0.0005234368,0.0013590021,0.00044486966],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63185614,0.0045497,0.14008558,0.0026708008,0.025317097,0.00024700232,0.00022507229,0.009875445,0.013648851,0.00034483612,0.0106513705,0.16052812],"study_design_scores_gemma":[0.1406409,0.13702635,0.6468202,0.000526555,0.030938579,0.0011222524,0.00026605622,0.013085144,0.010439292,0.0010694239,0.017895984,0.00016926244],"about_ca_topic_score_codex":0.0007788126,"about_ca_topic_score_gemma":0.0018800345,"teacher_disagreement_score":0.003217368,"about_ca_system_score_codex":0.001074666,"about_ca_system_score_gemma":0.0007228801,"threshold_uncertainty_score":0.017015278},"labels":[],"label_agreement":null},{"id":"W4403712090","doi":"10.1016/j.ejcskn.2024.100274","title":"Solar elastosis correlates with high tumor mutation burden and better 5-year disease-specific survival in patients with stage II/III melanoma","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Melanoma Institute Australia; Dartmouth Cancer Center; York University; Dartmouth College; Huntsman Cancer Institute; National Cancer Institute; Cleveland Clinic; Memorial Sloan-Kettering Cancer Center; University of North Carolina at Chapel Hill; National Institutes of Health; Yale University","keywords":"Stage (stratigraphy); Melanoma; Medicine; Disease; Overall survival; Internal medicine; Oncology; Mutation; Cancer research; Biology; Genetics; Gene","score_opus":0.006024202446509326,"score_gpt":0.20858190153793518,"score_spread":0.20255769909142585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403712090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993358,0.00018200511,0.00010907,0.000020165458,0.00000261019,0.0000024539017,0.00012109791,0.0000034516736,0.00022324822],"genre_scores_gemma":[0.9997291,0.000033778986,0.000052766085,0.000005839511,0.000004282141,0.0000012602577,0.00010093934,7.5008376e-7,0.000071270944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998727,0.00003062682,0.0000141126975,0.000037160593,0.000024254927,0.00002122978],"domain_scores_gemma":[0.9992968,0.00012026604,0.00038058104,0.00004272033,0.000046712477,0.00011292218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002345306,0.00018437802,0.00020812386,0.00041952633,0.00020992612,0.0003653362,0.000116213625,0.00023593978,0.0015728425],"category_scores_gemma":[0.0010453828,0.00012486106,0.00019823031,0.00035704978,0.00016079922,0.00018284944,0.00023681694,0.00027691352,0.00019114677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009018427,0.000006871724,0.9981406,0.0000039699626,0.000017520973,0.00006500519,0.000012836308,0.000031633514,0.0009027484,0.000005976353,0.000024742678,0.0006978611],"study_design_scores_gemma":[0.0000017936178,0.00003974288,0.9992372,0.0000016134488,0.000010854318,0.00036757,0.000030305806,0.0001440726,0.00009077036,0.000015307569,0.00005996791,9.92474e-7],"about_ca_topic_score_codex":0.0008363692,"about_ca_topic_score_gemma":0.001159227,"teacher_disagreement_score":0.0015728425,"about_ca_system_score_codex":0.00007924384,"about_ca_system_score_gemma":0.00009909601,"threshold_uncertainty_score":0.005261719},"labels":[],"label_agreement":null},{"id":"W4407240950","doi":"10.1016/j.ejcskn.2025.100284","title":"Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Type 2 diabetes; Cancer; Oncology; Body mass index; Index (typography); Diabetes mellitus; Alternative medicine; Pathology; Endocrinology; Immunotherapy; Computer science","score_opus":0.03411272885735226,"score_gpt":0.36545527000434735,"score_spread":0.3313425411469951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407240950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524456,0.0033386447,0.00018964606,0.00025888192,0.00009487328,0.00013223478,0.0002569256,0.000010601684,0.00047362325],"genre_scores_gemma":[0.99789184,0.00057093566,0.00030463087,0.00018081619,0.000109102235,0.00011857639,0.00034723664,0.0000040460345,0.00047280997],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9982503,0.0013382704,0.00007093155,0.0001454655,0.00009147982,0.000103531296],"domain_scores_gemma":[0.9979177,0.0008763248,0.0006633043,0.00015504796,0.000060549155,0.000327076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005548704,0.00082929956,0.0013320919,0.00025321238,0.00019148899,0.000833803,0.0005289899,0.0009036487,0.0016642498],"category_scores_gemma":[0.0037230558,0.00043692978,0.0017016506,0.00029775032,0.0005472972,0.0005121739,0.00034024424,0.0013027807,0.00011439237],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.913347,0.0021485414,0.052344184,0.0005334686,0.0034748728,0.000057321944,0.000059837996,0.0016463785,0.004796042,0.00012859573,0.000976664,0.02048711],"study_design_scores_gemma":[0.43008056,0.16235723,0.37914398,0.0002187315,0.01212887,0.00030744777,0.000109444205,0.009025108,0.0029181296,0.00060626696,0.0029947588,0.000109544555],"about_ca_topic_score_codex":0.0007636444,"about_ca_topic_score_gemma":0.0017802047,"teacher_disagreement_score":0.005548704,"about_ca_system_score_codex":0.000525013,"about_ca_system_score_gemma":0.0006834672,"threshold_uncertainty_score":0.029344678},"labels":[],"label_agreement":null},{"id":"W4409143650","doi":"10.1016/j.ejcskn.2025.100656","title":"Overall survival in patients with metastatic uveal melanoma (MUM) treated with local therapy modality and tebentafusp in a real-world setting","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Melanoma; Modality (human–computer interaction); Medicine; Metastatic melanoma; Treatment modality; Oncology; Internal medicine; Cancer research; Computer science; Artificial intelligence","score_opus":0.011760803675786916,"score_gpt":0.299756122073091,"score_spread":0.2879953183973041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409143650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987251,0.0006040857,0.000029020235,0.000058620924,0.000006749006,0.000004026178,0.00020115856,0.000002301291,0.00036898436],"genre_scores_gemma":[0.99953294,0.00014725831,0.000015901942,0.00002916965,0.000008480072,0.0000036811718,0.00017868662,5.9201375e-7,0.00008330393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99984944,0.000036047095,0.000010138144,0.000030822364,0.000015725507,0.000057860543],"domain_scores_gemma":[0.9998178,0.000035769466,0.000059840007,0.0000073408146,0.000015411702,0.000063958185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002246131,0.00014026382,0.00026102774,0.0002571925,0.00027447718,0.0003963061,0.00014302401,0.0002766441,0.00092679483],"category_scores_gemma":[0.0006012809,0.000077808014,0.000435401,0.00035427252,0.00018285954,0.00029256087,0.00029169803,0.00029849357,0.00009664794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042738663,0.00020702938,0.9794685,0.000080848426,0.00021348533,0.0010340438,0.00021440572,0.00052065105,0.0010763773,0.000060044436,0.0006369995,0.01221378],"study_design_scores_gemma":[0.00011141478,0.0018749482,0.99384177,0.00002163296,0.00024920446,0.0013717754,0.0005601086,0.00057369145,0.00017747495,0.00008719115,0.0011174807,0.000013251359],"about_ca_topic_score_codex":0.0030999533,"about_ca_topic_score_gemma":0.0059455796,"teacher_disagreement_score":0.0030999533,"about_ca_system_score_codex":0.00052062445,"about_ca_system_score_gemma":0.00028662497,"threshold_uncertainty_score":0.0061638355},"labels":[],"label_agreement":null},{"id":"W4409143683","doi":"10.1016/j.ejcskn.2025.100681","title":"Once in a blue moon: A rare, metastatic malignant blue nevus","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Tellabs (Canada)","funders":"","keywords":"Blue nevus; Dermatology; Medicine; Melanoma; Nevus; Cancer research","score_opus":0.0157537423049103,"score_gpt":0.2996006327630199,"score_spread":0.2838468904581096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409143683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820102,0.0053131483,0.003161262,0.0009548483,0.0001587618,0.00008072803,0.0001307362,0.00013720036,0.008053154],"genre_scores_gemma":[0.9972108,0.00070044963,0.00094904687,0.0002305212,0.00017606538,0.000011895702,0.00004764906,0.000014847239,0.0006588529],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99967635,0.000043787215,0.000019777974,0.00008199134,0.000078859244,0.00009927114],"domain_scores_gemma":[0.99896276,0.00026373228,0.0002904449,0.00009617507,0.00006259628,0.00032424036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019221357,0.0010077275,0.00060206745,0.0008900885,0.0013488259,0.00092488376,0.000584133,0.002267115,0.0017693073],"category_scores_gemma":[0.0017591404,0.00045849726,0.00038733153,0.00052894553,0.00084150734,0.00087820605,0.0008501643,0.0013250319,0.0007967375],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030915133,0.000027947533,0.013007705,0.000036467944,0.000009637468,0.98122174,0.00010943561,0.000099960635,0.0024636944,0.00021332075,0.00035294998,0.002426183],"study_design_scores_gemma":[0.000005155357,0.000030973762,0.003237595,0.000007947707,0.000005454991,0.9956161,0.000068726615,0.00019982713,0.000237311,0.00015224086,0.0004350789,0.0000036024082],"about_ca_topic_score_codex":0.00076696486,"about_ca_topic_score_gemma":0.0015981353,"teacher_disagreement_score":0.002267115,"about_ca_system_score_codex":0.0003923921,"about_ca_system_score_gemma":0.00028924827,"threshold_uncertainty_score":0.00591892},"labels":[],"label_agreement":null},{"id":"W4409144909","doi":"10.1016/j.ejcskn.2025.100586","title":"A Phase 3 trial of fixed-dose combination of fianlimab + cemiplimab vs relatlimab + nivolumab in patients with unresectable or metastatic melanoma","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Phase (matter); Metastatic melanoma; Radiology; Cancer research; Immunotherapy; Cancer; Physics","score_opus":0.01461065501911946,"score_gpt":0.3161808704942925,"score_spread":0.30157021547517304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409144909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862705,0.0040866635,0.0007096691,0.0013139946,0.00095749664,0.0019734427,0.0011842464,0.00018618065,0.003317944],"genre_scores_gemma":[0.9880824,0.001620478,0.0015792733,0.0014793845,0.00038528652,0.0017098625,0.0015932564,0.000054555323,0.0034955319],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99941754,0.00023958663,0.000020825464,0.00013288145,0.00003559402,0.00015349797],"domain_scores_gemma":[0.9992398,0.00017499243,0.00010225945,0.000066708475,0.00003710252,0.0003792062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001817514,0.0020794314,0.0031259775,0.0005622323,0.0005713647,0.0016923123,0.0013850802,0.0017110582,0.0072136633],"category_scores_gemma":[0.0013281204,0.00079561124,0.0029964251,0.00045794804,0.0013490475,0.0018424024,0.00046365891,0.006414501,0.001683465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9371251,0.018410068,0.0008304625,0.00038599916,0.0011441205,0.00006188656,0.000102355305,0.0015033359,0.0046208096,0.00019917398,0.0021263903,0.033490185],"study_design_scores_gemma":[0.8141434,0.18000172,0.0025179933,0.000028716267,0.00042545702,0.00006509563,0.00004510255,0.0009961992,0.0004972903,0.0002908355,0.0009599189,0.000028150826],"about_ca_topic_score_codex":0.0016702397,"about_ca_topic_score_gemma":0.0039083785,"teacher_disagreement_score":0.0072136633,"about_ca_system_score_codex":0.0014198641,"about_ca_system_score_gemma":0.0015399035,"threshold_uncertainty_score":0.024132073},"labels":[],"label_agreement":null},{"id":"W4409145217","doi":"10.1016/j.ejcskn.2025.100496","title":"Development of lymphoid aggregates in metastatic uveal melanoma (mUM) tumors treated with tebentafusp","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Metastatic melanoma; Melanoma; Medicine; Lymphatic system; Pathology; Cancer research; Oncology","score_opus":0.009475032897688683,"score_gpt":0.25658775431144637,"score_spread":0.24711272141375767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409145217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516344,0.0011771827,0.0012752474,0.00006131771,0.000028165545,0.00009339212,0.0001368886,0.00012100634,0.001943392],"genre_scores_gemma":[0.9983151,0.00019110578,0.0006540076,0.000027735347,0.000009850872,0.000031728185,0.00011935669,0.000005927341,0.0006452429],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999238,0.00001217723,0.000006688824,0.000018510138,0.000018674895,0.000020150286],"domain_scores_gemma":[0.9998752,0.000025444451,0.00003680724,0.000014297458,0.000011201887,0.000037045967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018225813,0.0002635457,0.00022623474,0.00041003447,0.00024534797,0.00017237241,0.0001614825,0.00031457737,0.0010597277],"category_scores_gemma":[0.00015860748,0.00013308572,0.0002227829,0.00009515196,0.00018283201,0.0001343904,0.0001954502,0.00040319184,0.00026159605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000983149,0.00022169026,0.0022151053,0.000100000856,0.000022973996,0.0035856226,0.000095170464,0.00022993976,0.9882112,0.00017297427,0.000120057,0.0040420936],"study_design_scores_gemma":[0.0003578796,0.0070600905,0.06828022,0.000026693167,0.00019513474,0.017301152,0.000119699864,0.005342757,0.8948144,0.00028025243,0.006204528,0.000017270355],"about_ca_topic_score_codex":0.00080293434,"about_ca_topic_score_gemma":0.0006363495,"teacher_disagreement_score":0.0010597277,"about_ca_system_score_codex":0.00032191467,"about_ca_system_score_gemma":0.00019857194,"threshold_uncertainty_score":0.003545165},"labels":[],"label_agreement":null},{"id":"W4414823153","doi":"10.1016/j.ejcskn.2025.100757","title":"Defining melanoma quality indicators: A modified Delphi approach","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Delphi Technique in Research","field":"Social Sciences","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"William Osler Health System; Doug Bragg Enterprises (Canada); Sunnybrook Health Science Centre; University of Toronto; Western University; Health Sciences Centre; McMaster University Medical Centre; Women's College Hospital; Lakeridge Health; University of Ottawa; Oakville Public Library; Mount Sinai Hospital; Princess Margaret Cancer Centre; McMaster University; Queen's University; Cancer Care Ontario","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Delphi method; Likert scale; Delphi; Quality (philosophy); Quality assurance; Melanoma; Mucosal melanoma; Health care","score_opus":0.10227402289945149,"score_gpt":0.4835386961224877,"score_spread":0.3812646732230362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414823153","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23446633,0.0011960407,0.5766198,0.009022069,0.00037506028,0.15361586,0.0010265652,0.00035157127,0.023326749],"genre_scores_gemma":[0.2790331,0.0007255338,0.6274391,0.0012447942,0.00006370043,0.089005716,0.0003543947,0.00005465474,0.002078949],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.7408555,0.22339895,0.01547133,0.004719196,0.011405467,0.0041494933],"domain_scores_gemma":[0.8791149,0.08142464,0.0064052246,0.005418443,0.02579522,0.0018415451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.18252055,0.0021876507,0.0015690946,0.009424325,0.004711097,0.0039459276,0.0030801701,0.001997687,0.0052028606],"category_scores_gemma":[0.14865036,0.0015337688,0.0023239926,0.005394301,0.006178746,0.0044557345,0.012403219,0.0030818398,0.0010607182],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016214268,0.00094295904,0.016460737,0.011800574,0.00058317673,0.0011155908,0.4449955,0.011221713,0.016419938,0.06886076,0.01193624,0.41404146],"study_design_scores_gemma":[0.0013813984,0.0046870583,0.036805157,0.012829754,0.00050130783,0.0019342342,0.5494641,0.0545829,0.014590243,0.20570327,0.11638901,0.0011315562],"about_ca_topic_score_codex":0.0039304104,"about_ca_topic_score_gemma":0.0049809013,"teacher_disagreement_score":0.18252055,"about_ca_system_score_codex":0.009910801,"about_ca_system_score_gemma":0.02148598,"threshold_uncertainty_score":0.9652725},"labels":[],"label_agreement":null}]}